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Abstract
Background: Dendritic cells (DCs) are highly specialized cells, which capture antigen in peripheral tissues and migrate to
lymph nodes, where they dynamically interact with and activate T cells. Both migration and formation of DC-T cell contacts
depend on cytoskeleton plasticity. However, the molecular bases governing these events have not been completely
defined.
Methodology/Principal Findings: Utilizing a T cell-dependent model of arthritis, we find that PLCc22/2 mice are protected
from local inflammation and bone erosion. PLCc2 controls actin remodeling in dendritic cells, thereby affecting their
capacity to prime T cells. DCs from PLCc22/2 mice mature normally, however they lack podosomes, typical actin structures
of motile cells. Absence of PLCc2 impacts both DC trafficking to the lymph nodes and migration towards CCL21. The
interaction with T cells is also affected by PLCc2 deficiency. Mechanistically, PLCc2 is activated by CCL21 and modulates Rac
activation. Rac1/22/2 DCs also lack podosomes and do not respond to CCL21. Finally, antigen pulsed PLCc22/2 DCs fail
to promote T cell activation and induce inflammation in vivo when injected into WT mice. Conversely, injection of WT DCs
into PLCc22/2 mice rescues the inflammatory response but not focal osteolysis, confirming the importance of PLCc2 both
in immune and bone systems.
Conclusions/Significance: This study demonstrates a critical role for PLCc2 in eliciting inflammatory responses by
regulating actin dynamics in DCs and positions the PLCc2 pathway as a common orchestrator of bone and immune cell
functions during arthritis.
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Introduction
Dendritic cells (DCs) constitute a unique bridge between the
innate and the adaptive immune system. They are potent antigen
presenting cells with the specific ability to stimulate naı ¨ve T cells
and control T cell responses [1]. For their T cell priming capacity,
DCs actively participate in development of autoimmune condi-
tions. In particular, several reports support the importance of DCs
during rheumatoid arthritis, a highly inflammatory disease
characterized by proliferation of synovial tissue and associated
joint destruction [2]. It is generally agreed that the arthritic disease
process involves abnormal presentation of self-antigens by antigen
presenting cells, leading to activation of autoreactive T lympho-
cytes, that are a significant component of RA pathogenesis [3].
Histological studies in patients showed that DCs cluster with T
cells close to blood vessels, and presence of T cell infiltrates in the
synovium are often observed [4,5,6]. Furthermore, experimental
animal studies have shown that DCs pulsed with collagen are able
to induce autoimmune arthritis after transfer to joints [6],
suggesting that DCs play an active role during the inductive
phase of inflammation. For all these reasons, a lot of efforts have
been spent in trying to elucidate the mechanisms controlling DC
functions, as a way to target T cell responses.
DCs are activated in the periphery where they internalize and
process the antigen [7,8]. Next, DCs migrate to the lymph nodes
where they present the antigen on MHC molecules, and the
process culminates with activation of reactive T cells. DC
migration is ensured by presence of podosomes, adhesive
structures mediating short-lived and low-affinity interactions with
the substrate. Podosomes are made by a core of actin bundles
surrounded by a ring of vinculin and other actin regulatory
proteins [9]. They are highly dynamic structures, fast assembled
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toward the migratory stimuli. Once DCs reach the lymph nodes,
podosomes are replaced by long membrane extensions, called
dendrites, which favor the interaction with potentially reactive T
cells [5]. Dynamic changes in the actin cytoskeleton are controlled
by the Rho family of small GTPases. In particular, Rac has been
reported to be a critical player in cell motility in various cell types
[10,11,12]. Rac1,22/2 DCs have migratory defects in vivo and
fail to induce T cell priming due to impaired interactions with T
cells [13]. The signaling pathway governing Rac activation in DCs
is still under investigation.
Phospolipase C gamma 2 (PLCc2), an enzyme that hydrolyzes
Phosphatidylinositol(4,5)-biphosphate to generate the two second
messengers inositol(1,4,5)-trisphosphate and diacylglycerol, is
implicated in actin cytoskeletal reorganization in osteoclasts and
neutrophils [14,15,16]. Importantly, PLCc22/2 mice are
protected from inflammation and consequent bone loss in the
serum transfer arthritis model due to defective neutrophil
activation [14]. Another consequence of PLCc2 deficiency is
decreased B cell number, while PLCc22/2 T cells develop
normally [17,18], and defective osteoclast differentiation and
function [15,16]. Interestingly, PLCc2 activation has also been
observed in DCs in response to LPS [19], however the phenotype
of PLCc22/2 DCs, including their capacity to activate T cells,
remains to be elucidated.
In this study we explored the contribution of PLCc2i nD C
functions as well as in the development of a T cell dependent
model of arthritis in vivo. Our results indicate that PLCc2i s
involved in actin cytoskeleton reorganization and Rac-activation
in DCs thereby modulating their trafficking to the lymph nodes
and their ability to interact with T cells. Furthermore, we show
that PLCc2 is critically required for progression of autoimmune
arthritis by affecting DC-mediated T cell priming and focal
osteolysis by modulating osteoclast responses.
Results
PLCc22/2 Mice Are Protected from mBSA-Induced
Arthritis
Considering the importance of PLCc2 in B cell develop-
ment, neutrophil function and osteoclastic bone resorption
[14,15,16,17,18,20], we hypothesized that PLCc2 could be central
to both the inflammatory and the osteolytic response associated with
the arthriticdisease. Inorder to definethe potential roleof PLCc2i n
the development of inflammatory arthritis we employed an
established model of antigen-induced arthritis (AIA), in which WT
and PLCc22/2 mice were immunized with methylated BSA
(mBSA), followed by induction of acute local inflammatory response
by a single knee injection of mBSA (or PBS as a negative control).
Induction of arthritis in WT mice led to severe local joint
inflammation, characterized by pronounced cellular infiltration
and osteoclast recruitment with associated bone destruction
compared to PBS control knees (Figure 1A,B and 2A,B). In contrast,
PLCc22/2 animals showed no clinical signs of knee swelling,
undetectable cellular infiltration or pannus formation in the joint
space, and no osteoclast recruitment or bone erosion following the
local injection of mBSA (Figure 1C,D and 2A,B). The protection of
PLCc22/2 mice from induction of arthritis was not due to absence
of mature B cells, since PLCc22/2 mice adoptively transferred
with WT B cells (Figure S1) were still resistant to development of the
disease (Figure 1E,F and 2A,B). In line with this observation, muMT
mice, which lack B cells, developed inflammation in response to
mBSA and showed increase OC number and signs of bone erosion
as their WT counterpart (Figure 1G,H and 2A,B).
T cells are the primary players during the inductive phase of
inflammatory arthritis [21]. To increase our understanding of the
impaired inflammatory response observed in PLCc22/2 mice,
we analyzed T cell activation after induction of the disease.
Paralleling the massive cellular infiltrate observed in the mBSA
injected knees of WT and muMT B cell-deficient mice, T cells
isolated from inguinal lymph nodes of these animals released IL-2,
TNFa and IFNc when restimulated in vitro with mBSA
(Figure 2C). In contrast, mBSA-dependent production of T cell
cytokines in samples from PLCc22/2 mice or PLCc22/2 mice
adoptively transferred with WT B cells was barely detectable
(Figure 2C), suggesting a requirement of PLCc2 for correct T cell
activation in vivo. Importantly, PLCc22/2 T lymphocytes can
release inflammatory cytokines when activated in vitro with PMA
and ionomycin (Figure S2), confirming that PLCc2 does not
directly control T cell function [22,23]. Thus, deletion of PLCc2
confers protection against the development of mBSA-induced
arthritis due to defective antigen-dependent T cell activation.
PLCc2 Controls Actin Organization in Mature DCs
DCs are potent inducers of naı ¨ve T cell responses [1]. We
hypothesized that PLCc2 might regulate T cell activation by
affecting DC maturation or function. To determine if PLCc2 was
required for development of DCs, we generated WT and
PLCc22/2 DCs from bone marrow precursors in the presence
of GM-CSF (Figure 3A). Expression of CD11c and upregulation of
maturation markers (CD80, CD86, CD40) in response to LPS
stimulation were similar between WT and mutant cells (Figure 3B),
as well as expression of MHC I (not shown) and MHC II
molecules (Figure 3B). Morphologically, consistent with LPS-
induced DC maturation, WT DCs assumed an elongated shape,
with numerous filamentous membrane extensions protruding from
their cell bodies (Figure 3C top panel). Enrichment of podosomes,
short lived dotted-like actin structures (Figure 3D top panel; in
green) surrounded by a ring of vinculin (Figure 3D top panel;
in red), were also seen at the protruding body of WT cells. In
contrast, PLCc22/2 DCs appeared larger and more round
(Figure 3C bottom panel). Actin staining (in green) revealed
absence of long membrane extensions, and fewer number of
abnormal podosomes (Figure 3D bottom panel; in green), lacking
the external ring of vinculin (Figure 3D bottom panel in red) and a
specific cellular localization as observed in WT DCs. Thus, while
not affecting expression of DC maturation markers, PLCc2
modulates actin reorganization in mature DCs.
PLCc2 Controls DC Migration by Affecting CCR7
Signaling and Rac Activation
Podosomes are dynamic actin structures, typical feature of
highly motile cells[9,24,25]. The aberrant podosome organization
observed in PLCc22/2 DCs suggested a role for PLCc2 in cell
motility. To evaluate this possibility, we employed a competitive
homing assay in which we coinjected a 1:1 mixture of differentially
labeled WT (low CFSE) and PLCc22/2 (high CFSE) DCs into
the footpad of WT mice and analyzed by FACS analysis the
number of cells reaching the draining popliteal lymph nodes 2
days later. Surprisingly, we observed that PLCc22/2 DCs had
significantly reduced ability to reach the lymph nodes compared to
WT cells (Figure 4A and Figure S3). A similar result was observed
when WT DCs were labeled with high CFSE and PLCc22/2
DCs with low CFSE (not shown). Signs of defective migration were
also confirmed in vitro, when we monitored the chemotactic
response of DCs towards CCL21 (Figure 4B). While WT DCs
efficiently migrated trough the pore of the transwell chamber
(59+/217 cells/field), the number of migrating PLCc22/2 DCs
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impaired migration, PLCc2 was activated downstream of CCR7
G Protein Coupled Receptor, as activation of ERK was abolished
in PLCc22/2 DCs stimulated with CCL21 (Figure 4C). In line
with the cytoskeletal abnormalities, activation of the small GTPase
Rac was significantly dampened in PLCc22/2 DCs in response
to the chemokine (Figure 4D). Similarly to PLCc22/2 DCs,
Rac1,22/2 DCs fail to migrate in response to CCL21 (Figure 4E)
due to impaired CCR7 activation, as ERK phosphorylation in
response to CCL21 was significantly dampened in the double KO
Figure 1. PLCc22/2 mice are protected from mBSA-induced arthritis independently of B cells. WT (A,B), PLCc22/2 (C,D), PLCc22/2
mice transferred with WT B cells (E,F) and muMT B cell-deficient mice (G,H) mice were immunized with mBSA and injected intraarticularly with mBSA
to induce arthritis or with PBS as a negative control. Histological sections of control PBS or mBSA injected knees were TRAP stained. Cellular infiltrates
(stars), osteoclasts (red cells) and bone erosion (arrows) are depicted. Images were taken using a Nikon inverted microscope and a CoolSnap camera,
magnification 206.
doi:10.1371/journal.pone.0008909.g001
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in Rac1,22/2 DCs (Figure 4F), indicating that PLCc2 modulates
DC motility via Rac activation downstream of CCR7 receptor.
To further explore the possibility that Rac modulates podosome
organization in DCs, WT and Rac1/22/2 DCs matured with
LPS were stained for actin and vinculin. The majority of Rac1/
22/2 DCs lack podosomes (86+/22% cells compared to only
25+/27% cells without podosomes in WT DCs). Similarly to
PLCc2 deficient DCs, the few cells that display dotted-like actin
structures which resemble the podosomes observed in WT cells
(Figure 4G top panels, arrow points to podosomes), lack the ring of
vinculin surrounding the actin core (Figure 4G bottom panels).
PLCc2 Is Required for DC:T Cell Interaction
Podosomes are active dynamic structures involved in cell
migration [9,24,25] and cell:cell interactions [26]. Once DCs
reach the lymph nodes, they need to make contacts with
potentially reactive T cells to initiate T cell dependent responses.
In this phase a single DC can interact and activate multiple
reactive T cells. Thus, we wondered if PLCc2 was also modulating
the formation of DC:T cell contacts occurring during T cell
priming, a process known to be mediated by Rac [13]. To test this
hypothesis, we used time-lapse video microscopy to monitor the
interactions between antigen-loaded DCs with T cells. While WT
DCs appeared highly dynamic, projecting numerous membrane
extensions in the direction of the T cells (Figure 5A and Movie S1),
PLCc22/2 DCs were poorly motile, well anchored to their initial
position, and extended only few dendrites towards T cells
(Figure 5A and Movie S2). The quantification of DC cell
movement, as determined by nuclei displacement, clearly showed
that PLCc22/2 DCs failed to move towards the surrounding T
cells (Figure 5B). Furthermore, lack of directional cell body
Figure 2. PLCc22/2 mice display defective osteoclast recruitment and T cell activation in response to mBSA. (A–B) Histomorphometric
analysis was performed on knee sections using the metamorph software. Number of osteoclasts for bone perimeter (A) or percentage of eroded
surface (B) are depicted. Stars indicate a significant difference of p,0.005. (C) Inguinal lymph nodes were isolated from WT, PLCc22/2 or muMT B
cell deficient mice after induction of arthritis and cultured ex vivo in the presence of mBSA (50 mg/ml) for 3 days. T cell activation was assessed as
release of IL-2, TNFa and IFNc in the media following restimulation with the antigen. Stars underline statistical significant differences (p value,0.01)
(n=3).
doi:10.1371/journal.pone.0008909.g002
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stained with CD11c FITC and analyzed for purity by FACS after 9 days in culture with GM-CSF (A). Immature or mature DCs were stained with CD11c
FITC or CD11c PE together with H-2
d FITC, CD80 FITC, CD86 PE, CD40 PE and analyzed with FACS (B). (C–D) Cytoskeletal organization was visualized in
LPS-matured DCs by staining actin (green) and vinculin (red) using 206(C) or 1006(D) magnification. In WT cells podosomes appear as dotted actin
structures surrounded by a ring of vinculin (arrow indicates the podosome structures that are enlarged in the box on the right). In contrast, in
PLCc22/2 DCs, the actin dots are not surrounded by the belt of vinculin (see arrow and enlarged box).
doi:10.1371/journal.pone.0008909.g003
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8909Figure 4. PLCc2 is required for DC migration by regulating CCL21 signaling. (A) In vivo trafficking of mature WT and PLCc22/2 DCs to the
lymph nodes was assessed in a competitive homing assay. Low CFSE-labeled WT and high CFSE-labeled PLCc22/2 DCs were coinjected in a 1:1 ratio
into the footpad of WT mice and their recruitment to the draining popliteal lymph nodes was analyzed 2 days later as presence of CFSE+DCs. Data
represent the mean number of recovered cells +/2 standard deviation (n=4). (B) In vitro migration of mature WT and PLCc22/2 DCs was evaluated
in response to CCL21 using transwell chambers. (C) WT or PLCc22/2 mature DCs were stimulated with CCL21 for different time points and activation
of PLCc2 and ERK was evaluated by Western Blot. (D) Western blot analysis of active Rac1 pulldown was performed in WT and PLCc22/2 DCs
stimulated with CCL21 for 2 minutes. (E) In vitro migration of mature WT and Rac1/22/2 DCs was evaluated in response to CCL21 using transwell
chambers. (F) WT or Rac1,22/2 mature DCs were stimulated with CCL21 and protein lysates were subjected to Western Blot analysis. Each WB figure
is representative of 3 independent experiments. (G) Actin structures were visualized in mature WT or Rac1,22/2 DCs by staining of actin (green) and
vinculin (red). Magnification 1006. Podosomes depicted by arrows are enlarged in the box.
doi:10.1371/journal.pone.0008909.g004
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8909Figure 5. PLCc2 is required for DC:T cell contacts and T cell priming in vitro. (A) Antigen-pulsed WT or PLCc22/2 DCs were cocultured with
OT-II T cells and DC:T cell interactions were filmed for 30 minutes using time lapse microscopy. In panel A, individual frames from Movie 1 are
reported, together with superimposition of the initial frame (time 0:00) in red. Scale bar 10 mm. Magnification 606. (B) WT and PLCc22/2 DC mobility
was quantified by measuring nuclei displacement over time. Position of nuclei was measured every 2.5 minutes for 30 minutes. Figure represents the
average space traveled by nuclei of different cells +/2 standard deviation. Analysis was conducted using methamorph software. (C) Number of DC:T
cell interactions was counted as the average number of contacts formed by different DCs with T cells +/2 standard deviation. (D) CFSE-labeled OT-II T
cells were cocultured with WT or PLCc22/2 DCs in the presence of different concentrations of ovalbumin-peptides. After 3 days T cell proliferation
was assessed as CFSE dye dilution. The figure is representative of 3 independent experiments.
doi:10.1371/journal.pone.0008909.g005
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the number of DC:T cell interactions which were barely detectable
in the presence of PLCc22/2 DCs (Figure 5C).
We next tested the ability of PLCc22/2 DCs to prime T cells
in vitro, by culturing WT or PLCc22/2 DCs together with OT
II T cells and increasing concentrations of the cognate peptide for
ovalbumin. Paralleling the observation that PLCc2 modulated
DC:T cell interactions, PLCc22/2 DCs were less efficient than
WT DCs in inducing T cell proliferation, as determined by CFSE
dye dilution (Figure 5D).
PLCc2 Modulates DC-Mediated T Cell Activation In Vivo
To explore the in vivo relevance of our findings, we then
analyzed the capacity of PLCc22/2 DCs to trigger a T cell
response in a variant of AIA model evoked by administration of
antigen-loaded DCs. Specifically, WT recipient mice were
immunized with mature mBSA-pulsed WT or PLCc22/2 DCs
on days 0 and 7, followed by a local knee injection of mBSA on
day 21. In this context, only exogenously injected DCs have the
ability to present the antigen to endogenous WT T cells. When
WT mice were immunized with mBSA-pulsed WT DCs, they
developed visible signs of arthritis. Cellular infiltrates, pannus
formation and local bone erosion were visible in the mBSA
injected knee, and such changes were not detected in the control
knee injected with PBS (Figure 6A,B and 7E,F). In contrast,
development of the disease did not occur in WT mice injected with
mBSA-pulsed PLCc22/2 DCs (Figure 6C,D and 7E,F).
Consistent with the histological findings, T cells isolated from
Figure 6. PLCc22/2 DCs fail to induce arthritis when injected into WT mice. (A–D) WT mice were immunized with mBSA-pulsed WT (A,B) or
PLCc22/2 (C,D) DCs followed by intraarticular injection of mBSA to induce local inflammation or PBS as a negative control. Histological analysis of
mBSA-injected knee reveals insurgence of arthritis as indicated by presence of inflammatory infiltrates (stars), osteoclast recruitment (TRAP-stained
red cells) and bone erosion (arrows) in WT animals injected with WT but not PLCc22/2 DCs. Images were taken using a Nikon inverted microscope
and a CoolSnap camera, magnification 206. (E) Inguinal lymph nodes of mice treated as above were cultured ex vivo with mBSA (50 mg/ml) for 3 days
and T cell activation was determined as release of IL-2, TNFa and IFNc in the culture medium. Statistical significant differences are underlined by stars
(p value,0.01) (n=3).
doi:10.1371/journal.pone.0008909.g006
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cytokines when restimulated ex-vivo with mBSA (Figure 6E).
Importantly, injection of WT DCs into PLCc22/2 mice was
sufficient to rescue the inflammatory response, leading to massive
cellular infiltrate in the joint space (Figure 7). Confirming the
previously known role of PLCc2 as critical mediator of osteoclastic
formation and function, PLCc22/2 mice injected with WT DCs
were still protected from osteoclast recruitment in the knee space
and focal osteolysis (Figure 7). Collectively, these data suggest a
critical role for PLCc2 in inflammatory arthritis by affecting both
DC-mediated T cell activity and osteoclastic responses.
Discussion
In the past decade, the focus of rheumatoid arthritis (RA)
research has been to determine which cytokines and inflammatory
mediators are produced at the site of disease. However, biological
pharmacotherapy aimed at blocking the activity of inflammatory
Figure 7. WT DCs rescue inflammation but not focal osteolysis when injected in PLCc22/2 mice. (A–D) PLCc22/2 mice were immunized
with mBSA-pulsed WT (A,B) or PLCc22/2 (C,D) DCs followed by intraarticular injection of mBSA to induce local inflammation or PBS as a negative
control. Inflammatory infiltrates in B are depicted by stars. Magnification 206. (E,F) Histomorphometric analysis was performed on knee sections of
both WT or PLCc22/2 mice injected with WT and PLCc22/2 DCs. Number of osteoclasts for bone perimeter (E) or percentage of eroded surface (F)
was calculated using metamorph software.
doi:10.1371/journal.pone.0008909.g007
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disease progression [27]. We are now beginning to understand
that migration of inflammatory cells into the joints and DC:T cell
contacts are other important components of the disease,
specifically because adhesion molecules not only modulate tissue
infiltration, but also affect cell activation and cell-cell interactions.
Here we have identified PLCc2 as a critical component of the
immune response associated with RA by affecting DC trafficking
from peripheral tissues to the lymph nodes and DC:T cell
interactions required to initiate the local inflammation via
modulation of actin dynamics.
Despite the well known role of PLCc2i nBc e l lm a t u r a t i o n
[17,18], PLCc2 is also required for osteoclast differentiation and
function [15,16]. Indeed, PLCc2 deletion leads to an osteope-
trotic phenotype in vivo [16]. More recently, we have also found
that PLCc22/2 mice are protected from inflammation in the
serum transfer arthritis model [14], which is primarily dependent
on neutrophil recruitment and activation [28]. However, human
rheumatic disease is more complex, involving multicellular
responses and not only neutrophil infiltration in the joint space.
We now demonstrate that PLCc22/2 mice are also protected
from development of inflammation and tissue damage in a T cell
dependent model of arthritis, which more closely resembles the
complex pathophysiology of the human disease. Using mBSA as
antigen to induce arthritis, we found impaired T cell activation in
PLCc22/2 mice. However, T cells do not express PLCc2,
excluding the possibility that PLCc2 directly affects T cell
function [22,23]. B cells, which fail to fully mature in the absence
of PLCc2 [17,18], are neither the source of the defective T cell
response, sinceWTB cell transplantintoPLCc22/2 micefailed
to rescue the inflammatory response to mBSA. Additionally,
muMT B cell-deficient mice could develop the arthritic disease to
the same extent as WT animals. Thus, other inflammatory cells
modulating T cell activation are affected by the deletion of
PLCc2.
In the complex puzzle of arthritis, DCs are known to play a
crucial role as they are the most potent antigen presenting cells in
T cell responses [29,30]. When PLCc22/2 DCs were loaded
with the antigen ex vivo and injected into WT animals, they were
unable to induce inflammation or support T cell activation,
although similarly treated WT DCs were fully competent in the
same assays. In contrast, injection of WT DCs into PLCc22/2
mice fully restored the arthritic inflammatory response. Two
distinct events modulate the capacity of DCs to regulate T cell
activation: first, their ability to migrate from peripheral tissues to
secondary lymphoid organs upon antigen binding, and second, the
interaction with and activation of T cells in lymph nodes
[31,32,33]. We found that PLCc2 controls both events.
Migration of DCs to the lymph nodes is critical for induction of
T cell responses [4]. Lymph node homing of plasmacytoid DCs
has been suggested to be critical for regulatory T-cell development
and tolerance induction in a cardiac allograft transplant model
[34]. Our data clearly show that in absence of PLCc2 DCs fail to
home to the lymph nodes and PLCc22/2 mice do not develop
inflammatory arthritis. Even in the circumstance that some
PLCc22/2 DCs could reach the secondary lymphoid organs,
the in vitro imaging data suggest that lack of PLCc2 affects DC
ability to extend ruffles and long dendrites towards the adjacent T
cells. Consequently, PLCc22/2 DCs display defective T cell
priming in vitro and ex-vivo. We cannot rule out the possibility
that PLCc2 may also play a role in additional DC functions
occurring during T cell priming, such as presentation of the
antigen or production of cytokines [19,35,36] that support Th cell
differentiation. However, trafficking to the lymph nodes is an event
that occurs in the initial phase of T cell priming and DC:T cell
contacts precede T cell activation.
Mechanistically, these two, albeit distinct, DC functions require
active cytoskeleton rearrangements, as membrane protrusions
must form to activate the migratory machinery as well as to favor
cell:cell contacts. Although cell maturation occurs normally in the
absence of PLCc2, the null cells appear larger, lack long
membrane elongations that DCs form to interact with T cells,
and present abnormal podosome structures, characterized by
condensed actin dots not surrounded by the typical ring of
vinculin. We have previously reported a role for PLCc2 in actin
dynamics in osteoclasts. PLCc22/2 osteoclasts, like DCs, have
abnormal actin cytoskeleton, as they lack the typical belt of actin
which enables the cell to seal the acidic environment of the
resorptive lacunae, allowing bone dissolution. As a consequence of
aberrant resorption, PLCc22/2 mice have increased bone mass
in basal condition and now we show are also protected from
inflammatory-induced bone loss. Similarly to the osteoclasts, we
find that DCs have an abnormal podosome structure. It is not
clear how PLCc2 specifically modulates formation of podosomes,
as focal contacts, more stable adhesive structures, form normally in
PLCc22/2 DCs following short exposure to LPS stimulation
(Figure S4). In the osteoclasts, PLCc2 regulates c-Src activation
and membrane localization and c-Src null osteoclasts lack
podosomes[15]. It is possible that a similar mechanism occurs in
DCs, as vinculin, a Src substrate [37], fails to surround the
podosome actin core. Lack of these highly dynamic structures can
affect the capacity of the cell to rapidly rearrange the actin
cytoskeleton during cell migration or cell:cell contacts. Evidence
showing the importance of podosome organization in DC function
comes from Wasp deficient DCs, which lack podosomes, and
display trafficking defects [38] and impaired T cell activation [39].
Similarly, WASP-interacting-protein (WIP) deficient DCs lack the
typical belt of vinculin around the actin core of the podosome, fail
to polarize and form stabilized leading edges in response to
chemokine gradient and consequently are poorly motile [25].
However the physiological importance of these actin-regulating
molecules in DC function in a disease context in vivo has never
been reported.
Activation of the small Rho GTPase Rac is also essential for cell
polarization and membrane protrusions at the leading edge of
migratory cells [10,11,12,13]. We now provide new evidences that
Rac deficiency impairs podosome formation in LPS matured DCs.
Importantly, Rac1,22/2 DCs have severe migratory defects and
cannot extend polarized dendrites towards T cells [13], thereby
fail to promote T cell activation, similarly to what we observed in
PLCc22/2 DCs. Mechanisms of Rac activation in DCs are
unclear. In plasmacytoid, but not myeloid DCs, DOCK2 controls
cell migration by functioning downstream of chemokine receptors
and activating Rac [40]. Direct interaction between constitutively
active Rac and the split pleckstrin domain of PLCc2 has been
recently described in COS cell line [41]. Indeed, we find Rac to be
activated in response to the chemokine CCL21 and regulated by
PLCc2 in bone marrow derived DCs. Conversely, PLCc2
phosphorylation is normal in Rac1/2 deficient DCs. Thus, our
data position PLCc2 as a critical modulator of Rac activity
downstream of CCL21 receptor, CCR7. This data are further
supported by the similar morphological, functional and signaling
defects observed in both PLCc22/2 and Rac1/22/2 DCs.
DCs constitute a unique link between innate and adaptive
immunity, and their targeting during inflammatory conditions
may represent a valid alternative to current therapies which are
often specific for only one component of the immune response
[27]. Our in vivo animal studies unequivocally support the
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inflammatory response associated with antigen-induced arthritis.
Moreover, previous studies showed that activation of PLCc2i n
DCs occurs downstream of several immune receptors, in particular
TLR4 [19] and Dectin-1[36,42]. Altogether, these data suggest
that PLCc2 is actively regulated in DCs during the course of an
inflammatory response.
We have previously reported that neutrophil activation is
impaired in PLCc22/2 mice [14]. Although we cannot exclude
that neutrophils also participate in the development of inflamma-
tion in the antigen-induced model of arthritis, the finding that
injection of antigen-pulsed PLCc22/2 DCs in WT mice is not
sufficient to initiate the inflammatory disease, highlights the
importance of DC motility and actin dynamics during DC-
mediated activation of T cell responses. In agreement with this
posture, injection of WT DCs in PLCc22/2 mice rescues
inflammation, however bone resorption is still impaired. Focal
osteolysis is a deleterious consequence of arthritic inflammatory
conditions, reflected as bone pain, periarticular and appendicular
osteopenia, and impaired mobility. Here we provide evidences
that PLCc2 modulates bone loss independent from inflammation.
While our prior investigation has revealed a role for PLCc2i n
osteoclast formation and function under basal condition, now we
prove that this holds true even in the context of an inflammatory
condition known to be favorable for osteoclastic recruitment.
In summary, the importance of PLCc2 in osteoclasts [15,16]
and neutrophils [14,20], in conjunction with its role in DC-
mediated T cell activation here discussed, positions the molecule
as a point of convergence between bone and immune systems in
complex pathologies such as RA and other autoimmune diseases
characterized by an interplay between bone and immune cells.
Methods
Mice
PLCc22/2 mice have been previously described [18]. CD45.1
B6 congenic mice were purchased from Jackson lab. muMT B
cell-deficient mice and OT-II mice were kindly provided from Dr.
Virgin at Washington University. Rac1,22/2 cells were isolated
from dKO conditional mice, kindly provided by Dr. Ross at
Washington University (Rac22/2 mice X Rac1
fl/fl/LysoM
cre+/+ mice). All experiments were approved by the Washington
University School of Medicine animal care and use committee. All
the mice used in the experiment came from a B6 background.
mBSA-Induction of Arthritis
Mice were immunized on day 0 and day 7 by intradermal
injection at the base of the tail of 100 mg mBSA (Sigma-Aldrich)
emulsified in 0.1 ml Freund’s adjuvant (CFA on day 0 and IFA on
day 7, BD). At the same time 1 mg pertussis toxin (List Biological
Laboratories Inc.) was also injected intraperitoneally. Arthritis was
induced on day 21 by intraarticular injection of 100 mg of mBSA
in 10 ml PBS into the right knee, while the contralateral knee was
injected with PBS alone as a negative control. Mice were sacrificed
on day 32 and insurgence of arthritis was assessed by histological
examination of knee sections by H&E and TRAP staining.
B Cell Transfer
Splenic cells from WT CD45.1 congenic mice were depleted of
erythrocytes in red cell removal buffer (154 mM NH4Cl, 0.1 mM
EDTA, 10 mM NaHCO3) and B cells were purified using CD19
immunobeads (Mylteny Biotech). 20*10
6 purified B cells were
injected into the tail vein of PLCc22/2 mice 1 day before the
mBSA immunization protocol was started. Presence of B cells
in the blood was assessed at day 21 by FACS analysis for
B220+CD45.1+ cells.
BMDC Isolation
DCs were isolated from total bone marrow cells harvested from
long bones and cultured for 7–10 days in complete medium
supplemented with 2% GM-CSF, as titrated from supernatants of
the GM-CSF secreting TOPO cell line. DCs were matured by
overnight treatment with 1 mg/ml LPS (Sigma-Aldrich) and,
where appropriate, pulsed with mBSA [50 mg/ml] for 4 hours
prior to maturation. For FACS analysis of DC cultures, the
following antibodies were utilized: CD11c FITC, CD11c PE,
CD80 FITC, CD86 PE and CD40 PE (from BD), H-2
d FITC
(from eBioscience).
Induction of Arthritis by DC Transfer
WT or PLCc22/2 DCs were pulsed with mBSA for 4 hours
and then matured o.n. with LPS. Recipient mice were then
immunized at day 0 and 7 by s.c. administration of these mBSA-
pulsed DCs (2*10
6 cells into each footpad). On day 21, arthritis
was induced by injection of mBSA [10 mg/ml] into the right knee,
while controlateral knee received PBS. Mice were sacrificed on
day 32 and histological examination was performed.
Restimulation of Draining Lymph Node Cells Ex Vivo
At the end of the in vivo experiments, mice were sacrificed and
draining inguinal lymph nodes removed. Single-cell suspensions
were prepared, and from each mouse all cells from each lymph
node were plated in 1 well of a 96 well/plate in 200 ml of RPMI
1640 containing 10% mouse serum for a total of at least 8 wells.
Cells were restimulated with 50 mg/ml mBSA in vitro for 3 days.
Supernatants were harvested after 3 days and cytokine production
was assessed using the TH1/TH2 assay kit from BD bioscience
according to the manufacture. Briefly, three bead populations with
distinct fluorescence intensities and coated with capture antibodies
specific for IL-2, IFN-c or TNF-a were mixed with the PE-
conjugated detection antibody and then incubated with samples or
standards for 2 hours. After washing, the samples were analyzed
with a FACScalibur and mean fluorescence was evaluated.
Immunofluorescence
DCs were seeded on glass coverslips at a concentration of
2*10
5 cell/ml and matured o.n. with LPS treatment. After
maturation, cells where fixed in 4% PFA (Polyscisnces), stained
with a mouse anti-vinculin antibody (Sigma) followed by
incubation with a secondary anti-mouse 564 antibody together
with phalloidin 488 (both from Molecular Probes). Coverslips were
analyzed using an Olympus IX70 inverted microscope with either
20X APO, or 100X APO. Images were captured with a CoolSnap
camera (Roper Scientific).
Competitive In Vivo DC Homing Assay
DCs from WT or PLCc22/2 mice were fluorescently labeled
with high (2 mM) or low (400 nM) CFSE and coinjected in the
ratio of 1:1 into each footpad of recipient WT mice (2*10
6 total
DCs for each footpad). After 2 days recipient mice were sacrificed,
draining popliteal lymph nodes were recovered and analyzed for
presence of CFSE+DCs by FACS.
DC Migration Assay In Vitro
5*10
5 matured DCs were seeded into the upper filter of 24 well
transwell plates (8 mm filters, Corning Incorporated) and allowed
to migrate towards CCL21 [10 mg/ml] (eBioscience) or control
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compartment for 10 minutes to allow migrated cells to adhere to
the bottom of the well. Cells were fixed, stained with crystal violet
and counted.
DC Stimulation, Western Blot and Rac Activation Assay
5*10
6 mature DCs starved overnight in 2% FBS were
stimulated with 10 mg/ml CCL21 (eBioscience). Cells were lysed
in RIPA buffer and equal amount of proteins were resolved by
SDS-PAGE to detect pPLCc2 or pERK (all from Cell Signaling).
For analysis of activation of Rac, 500 mg of lysate was subjected to
active Rac pulldown according to the manufacture protocol (Rac1
activation Kit, Pierce).
Time-Lapse Video Microscopy
DCs pulsed with ovalbumin-peptides (1000 nM) were seeded on
Glass bottom culture dishes (MatTek) at a final concentration of
2*10
5 cells/ml in L15 medium +10% FBS. After DCs adhered,
2*10
5 OT-II CD4+T cells were added to the culture. Pictures were
taken every 30 seconds using an Olympus IX70 inverted
microscope with a 60x APO lens and a CoolSnap camera (Roper
Scientific) starting 10 minutes after addition of T cells, for a
maximum of 30 minutes. Analysis of DC:T cell interactions was
performed using methamorph software (Universal Imaging
Corporation).
Antigen Presentation Assay
2*10
4 WT or PLCc22/2 immature DCs were plated in
96 well/plates and ovalbumin-peptides (from 0 to 1000 nM) were
added to the media. CD4+T cells purified from OT-II mice (CD4
immunobeads Mylteni Biotech) were labeled with CFSE (2 mM)
and added to the plates at a final concentration of 1*10
5 cells/well.
After 3 days, T cells were recovered, stained with an APC-
conjugated CD4 antibody (BD Bioscience) and T cell proliferation
was assessed by FACS analysis.
Statistics
Two-tailed Student’s t test was used for all comparisons, with a
P value of ,0.05 set as statistically significant.
Supporting Information
Figure S1 Efficiency of WT B cell transfer in PLCc22/2 mice.
The number of circulating B cells in PLCc22/2 mice was
evaluated 21 days after WT B cell transfer by FACS analysis of
peripheral blood. Donor cells were visualized by CD45.1 PE and
B220 FITC co-staining. PLCc22/2 mice not injected served as a
negative control. One representative FACS plot analysis is shown.
Found at: doi:10.1371/journal.pone.0008909.s001 (0.14 MB TIF)
Figure S2 PLCc22/2 T cells normally respond to PMA and
ionomycin in vitro. CD4+T cells from WT or PLCc22/2 mice
isolated from inguinal lymph nodes were stimulated in vitro with
PMA and ionomycin. After 3 days supernatant was recovered and
production of T cell specific cytokines determined.
Found at: doi:10.1371/journal.pone.0008909.s002 (0.07 MB TIF)
Figure S3 PLCc2 is required for DC homing to the lymph
nodes. In vivo migration of WT and PLCc22/2 DCs was
assessed in a competitive homing assay. Low CFSE-labeled WT
and high CFSE-labeled PLCc22/2 DCs were coinjected (1:1)
into the footpad of WT mice and their recruitment to the draining
popliteal lymph nodes was analyzed 2 days later. One represen-
tative FACS plot analysis is shown in the figure.
Found at: doi:10.1371/journal.pone.0008909.s003 (0.15 MB TIF)
Figure S4 PLCc22/2 DCs form normal focal adhesion
structures in response to short LPS stimulation. Cytoskeletal
organization was visualized in WT and PLCc22/2 DCs after
2 hour stimulation with LPS by staining actin (green) and vinculin
(red). Magnification 1006. Focal adhesions are depicted by
arrows.
Found at: doi:10.1371/journal.pone.0008909.s004 (2.24 MB TIF)
Movie S1 Interactions between WT DCs and T cells. Antigen-
pulsed WT DCs were cocultured with OT-II T cells and DC:T
cell interactions were filmed for 30 minutes using time lapse
microscopy.
Found at: doi:10.1371/journal.pone.0008909.s005 (10.31 MB
MPG)
Movie S2 Interactions between PLCc22/2 DCs and T cells.
Antigen-pulsed PLCc22/2 DCs were cocultured with OT-II T
cells and DC:T cell interactions were filmed for 30 minutes using
time lapse microscopy.
Found at: doi:10.1371/journal.pone.0008909.s006 (10.25 MB
MPG)
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